News

MELBOURNE, Australia and TORONTO, Feb. 12, 2019 /CNW/ - Cartherics Pty Ltd ("Cartherics") and panCELLa Inc. ("panCELLa") are pleased to announce their collaboration to research, develop and commercialize products for the treatment of cancer and other debilitating diseases using cell therapy.  panCELLa will integrate their exclusive FailSafeTM technology into Cartherics' proprietary homozygous HLA haplotype cells to bring the power of …

Cartherics and panCELLa announce collaborative agreement to develop pluripotent cell lines for cell therapy  Read More »

TORONTO, Nov. 14, 2018 /CNW/ - panCELLa is proud to announce the publication of "Linking a cell division and a suicide gene to define and improve cell therapy safety"  in the November 21st  2018 issue of Nature. Cell therapies hold enormous promise of new treatment and cures for many currently devastating degenerative diseases, including diabetes, arthritis, blindness, heart and lung diseases.  "Even …

panCELLa’s Exclusive FailSafe Cells Improve Cell Therapy Safety  Read More »

panCELLa Inc., an innovative biotechnology company, has announced today the recent completion of a $1M investment from Chiefswood Holdings Limited.  Terms of the financing were not disclosed.  This is the first outside capital for the company.